STUDY PROTOCOL article

Front. Aging Neurosci.

Sec. Neurocognitive Aging and Behavior

Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1584115

Protocol of a Randomized, Single-Blind, Controlled Trial of an 18-Month, Home-Based, High-Intensity, Exercise Intervention in Older, Cognitively Unimpaired APOE e4 Carriers

Provisionally accepted
Stephen  M RaoStephen M Rao1*Alexandria  L ChorbaAlexandria L Chorba1MJ  HelppiMJ Helppi1Alina  TuladharAlina Tuladhar1Amanda  PenkoAmanda Penko1Sarah  HolleySarah Holley1Brandon  NehlsBrandon Nehls1Sabrina  PaulinoSabrina Paulino1Matthew  C StreicherMatthew C Streicher1Audrey  ZhuAudrey Zhu1Kellie  BrueningKellie Bruening1Sally  DurgerianSally Durgerian1Katherine  A KoenigKatherine A Koenig1Mark  LoweMark Lowe1Stephen  E JonesStephen E Jones1Rachel  GaliotoRachel Galioto1Jagan  A PillaiJagan A Pillai1Lynn  M BekrisLynn M Bekris2James  B LeverenzJames B Leverenz2Anson  B RosenfeldtAnson B Rosenfeldt1Tamanna  SinghTamanna Singh1Gerald  J BeckGerald J Beck1J. Carson  SmithJ. Carson Smith3Jay  AlbertsJay Alberts1
  • 1Cleveland Clinic, Cleveland, Ohio, United States
  • 2University of Washington, Seattle, Washington, United States
  • 3University of Maryland, Baltimore, Maryland, United States

The final, formatted version of the article will be published soon.

The World Health Organization highlighted the potential protective role of exercise against cognitive decline, all-cause dementia, Alzheimer's disease (AD), and vascular dementia in healthy individuals. We have previously shown that exercise is particularly beneficial for older, cognitively unimpaired apolipoprotein E4 (APOE e4) carriers. A key unanswered question is whether a long-term, high-intensity aerobic exercise intervention initiated in a cohort of previously inactive older individuals at genetic risk for AD has neuroprotective properties. Design: CYCLE-AD is a randomized, single-blind, single-center, controlled trial of a home-based, high-intensity exercise intervention involving 150 older e4 carriers (ages 65-80 years) who are healthy, cognitively unimpaired, and physically inactive. Participants are randomized into two groups: Indoor Cycling (IC) or Usual and Customary Care (UCC) (target of 75 each). IC participants exercise 3x/week on an upright stationary cycle ergometer at a moderate-vigorous intensity for 18 months. Those in the UCC group are expected to maintain enrollment levels of activity.Outcomes: Comparison of IC and UCC groups on change in primary and secondary outcomes over baseline, 9-month, and 18-month evaluations. Primary outcomes are VO2peak (Fitness), 5-trial total recall on the Rey Auditory Verbal List Learning Test (Episodic Memory), and total hippocampal volume derived from structural MRI (Brain Atrophy). Secondary outcomes include comprehensive neurocognitive and physical function test batteries, MRI scans including structural and functional connectivity measures, and blood-based biomarkers. Hypotheses: Over an 18-month interval, physically inactive e4 carriers who engage in high-intensity aerobic exercise will demonstrate less cognitive decline and hippocampal atrophy than physically inactive e4 carriers who did not participate in a formal exercise program. Conclusion: Successful demonstration of a scalable, home-based, high-intensity aerobic exercise intervention in altering the trajectory of AD pathophysiology and its effects on cognitive functioning will transform AD treatment, improve patient outcomes and quality of life, and reduce health care costs. ClinicalTrials.com registration number: NCT04748861

Keywords: Alzheimer's disease, Exercise, Neuroprotection, APOE e4, randomized clinical trial

Received: 26 Feb 2025; Accepted: 25 Apr 2025.

Copyright: © 2025 Rao, Chorba, Helppi, Tuladhar, Penko, Holley, Nehls, Paulino, Streicher, Zhu, Bruening, Durgerian, Koenig, Lowe, Jones, Galioto, Pillai, Bekris, Leverenz, Rosenfeldt, Singh, Beck, Smith and Alberts. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Stephen M Rao, Cleveland Clinic, Cleveland, 44195, Ohio, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.